{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T04:00:44Z","timestamp":1780977644544,"version":"3.54.1"},"reference-count":3,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.msard.2026.107257","type":"journal-article","created":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T15:36:39Z","timestamp":1778945799000},"page":"107257","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["GLP-1 receptor agonists in multiple sclerosis: Weight loss without disease modification \u2014 Are we measuring the right outcomes?"],"prefix":"10.1016","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-7344-638X","authenticated-orcid":false,"given":"Mobeen","family":"Sajjad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7_Suppl_1","key":"10.1016\/j.msard.2026.107257_bib0001","article-title":"Exploring the effect of GLP-1 agonists on multiple sclerosis disease progression","volume":"104","author":"Ali","year":"2025","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2026.107257_bib0002","unstructured":"Rodin R., et al. GLP-1 receptor agonists in MS: weight loss without disease modification. Presented at: ACTRIMS Forum 2026; 2026; San Diego, CA. [Conference presentation; not yet peer-reviewed]."},{"issue":"1","key":"10.1016\/j.msard.2026.107257_bib0003","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3390\/pathophysiology33010005","article-title":"Is obesity a modifiable risk factor in multiple sclerosis? Mechanistic insights into neuroinflammation and oxidative damage","volume":"33","author":"Varra","year":"2026","journal-title":"Pathophysiology"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826002932?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826002932?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T03:35:45Z","timestamp":1780976145000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034826002932"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":3,"alternative-id":["S2211034826002932"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2026.107257","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"GLP-1 receptor agonists in multiple sclerosis: Weight loss without disease modification \u2014 Are we measuring the right outcomes?","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2026.107257","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107257"}}